Get an alert when STEVENAGE BIOSCIENCE CATALYST files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Cash

£1.6m

+4.6% vs 2025

Net assets

£4.2m

-1.8% lowest in 4 filed years

Employees

16

-5.9% vs 2025

Profit before tax

-£458k

+48.2% vs 2025

Accounts

4-year trend · Δ = latest vs prior filed period · latest reflected 2026-03-31

Metric Trend 2023-03-312024-03-312025-03-312026-03-31 Δ vs prior
Total income £5,094,304£5,458,653£4,091,025£5,215,789 +27.5%
Operating profit £3,565,677£612,902-£986,341-£489,522 +50.4%
Profit before tax £3,547,401£734,333-£884,373-£458,295 +48.2%
Net profit £2,824,971£613,892-£683,178-£76,520 +88.8%
Cash £4,019,795£2,109,056£1,544,048£1,614,937 +4.6%
Total assets less current liabilities £20,900,290£20,417,728£18,590,836£17,260,494 -7.2%
Net assets £4,371,977£4,985,871£4,302,693£4,226,171 -1.8%
Equity £4,371,977£4,985,871£4,302,693£4,226,171 -1.8%
Average employees 15171716 -5.9%
Wages ———— —
Directors' remuneration £321,434£372,747£390,472£258,191 -33.9%
Directors' pension contributions —£44,783£19,652£16,786 -14.6%
Highest paid director —£269,962£307,020£159,191 -48.1%

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2023-03-312024-03-312025-03-312026-03-31
Operating margin 70.0%11.2%-24.1%-9.4%
Net margin 55.5%11.2%-16.7%-1.5%
Return on capital employed 17.1%3.0%-5.3%-2.8%
Gearing (liabilities / total assets) 82.8%79.3%80.4%79.8%
Current ratio —1.52x1.06x1.06x
Interest cover ———-36.16x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Name history

Renamed 1 time since incorporation

  1. STEVENAGE BIOSCIENCE CATALYST 2010-08-02 → present
  2. STEVENAGE BIOSCIENCE PARK 2010-03-19 → 2010-08-02

Audit & accounting basis

Accounting basis
FRS 102 §1A
Reporting scope
Standalone (parent only)
Auditor
Menzies LLP
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“The directors believe that the company is well placed to manage its business risks successfully and they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future.”

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

4 active · 13 resigned

Name Role Appointed Born Nationality
DRUMMOND, Lynn, Dr Director 2023-05-01 Aug 1959 British
GREEN, Jonathan Alexander Director 2019-08-30 Mar 1957 British
HUNTER, Ann Jacqueline, Professor Director 2020-09-01 Nov 1956 British
PHADKE, Uday Prabhakar, Dr Director 2023-04-03 Jul 1952 British
Show 13 resigned officers
Name Role Appointed Resigned
ALLEN, Dave Director 2016-01-01 2020-08-31
BAXTER, Allan, Dr Director 2010-03-19 2015-01-06
BOUCHET, Veronique Anne, Dr Director 2012-05-01 2022-06-07
COOPER, John Director 2010-03-19 2016-07-05
FORSYTH, Sally Ann, Dr Director 2018-03-05 2026-05-02
NELKI, Daniel Director 2016-07-05 2017-04-05
PICARDO, Martino Director 2011-03-01 2017-06-23
RINK, Timothy, Dr Director 2010-07-30 2012-03-31
RIVERS, Graham Paul Director 2023-07-20 2026-05-20
TERLOUW, Clare Elizabeth Director 2019-08-29 2023-01-11
TOMLINSON, Ian Michael Director 2011-08-15 2020-08-31
WARD, Iain Stuart Director 2017-04-05 2018-07-31
WHEATCROFT, James Russell Director 2020-09-01 2023-07-20

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Glaxosmithkline Research & Development Limited Corporate entity Voting 25–50% 2016-04-06 Active
The Wellcome Trust Limited Corporate entity Voting 25–50% 2016-04-06 Active

Filing timeline

Last 20 of 93 total filings

Date Type Category Description
2026-10-15 AA accounts Accounts with accounts type full PDF
2026-06-02 TM01 officers Termination director company with name termination date PDF
2026-05-28 TM01 officers Termination director company with name termination date PDF
2026-04-03 CH01 officers Change person director company with change date PDF
2026-04-02 RP01AP01 officers Replacement filing of director appointment with name PDF
2026-04-02 CS01 confirmation-statement Confirmation statement with no updates PDF
2026-04-01 PSC05 persons-with-significant-control Change to a person with significant control PDF
2025-12-17 AA accounts Accounts with accounts type full PDF
2025-03-24 CS01 confirmation-statement Confirmation statement with no updates PDF
2024-12-19 AA accounts Accounts with accounts type full PDF
2024-03-20 CS01 confirmation-statement Confirmation statement with no updates PDF
2023-08-30 AP01 officers Appoint person director company with name date PDF
2023-08-29 TM01 officers Termination director company with name termination date PDF
2023-08-03 AA accounts Accounts with accounts type small
2023-08-01 MR04 mortgage Mortgage satisfy charge full PDF
2023-08-01 MR04 mortgage Mortgage satisfy charge full PDF
2023-08-01 MR04 mortgage Mortgage satisfy charge full PDF
2023-06-08 AP01 officers Appoint person director company with name date PDF
2023-06-08 AP01 officers Appoint person director company with name date PDF
2023-03-23 CS01 confirmation-statement Confirmation statement with no updates PDF

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
8

last 12 months

Capital events
0

last 24 months

Officers appointed
0

last 12 months

Officers resigned
2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Official Companies House page

Spotted an error, or named here and want to reply? Report it · How we handle corrections